Back to Search
Start Over
Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia
- Source :
- Cardiovascular Diabetology, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname, Dipòsit Digital de Documents de la UAB, Universitat Autònoma de Barcelona, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-11 (2021)
- Publication Year :
- 2021
- Publisher :
- BioMed Central, 2021.
-
Abstract
- Background Evidence from prospective cardiovascular (CV) outcome trials in type 2 diabetes (T2DM) patients supports the use of sodium–glucose co-transporter-2 inhibitors (SGLT2i) to reduce the risk of CV events. In this study, we compared the risk of several CV outcomes between new users of SGLT2i and other glucose-lowering drugs (oGLDs) in Catalonia, Spain. Methods CVD-REAL Catalonia was a retrospective cohort study using real-world data routinely collected between 2013 and 2016. The cohorts of new users of SGLT2i and oGLDs were matched by propensity score on a 1:1 ratio. We compared the incidence rates and hazard ratio (HR) for all-cause death, hospitalization for heart failure, chronic kidney disease, and modified major adverse CV event (MACE; all-cause mortality, myocardial infarction, or stroke). Results After propensity score matching, 12,917 new users were included in each group. About 27% of users had a previous history of CV disease. In the SGLT2i group, the exposure time was 60% for dapagliflozin, 26% for empagliflozin and 14% for canagliflozin. The use of SGLT2i was associated with a lower risk of heart failure (HR: 0.59; 95% confidence interval [CI] 0.47–0.74; p Conclusions In this large, retrospective observational study of patients with T2DM from a Catalonia, initiation of SGLT-2i was associated with lower risk of mortality, as well as heart failure and CKD.
- Subjects :
- Male
medicine.medical_specialty
Time Factors
Endocrinology, Diabetes and Metabolism
030209 endocrinology & metabolism
Heart failure
Type 2 diabetes
030204 cardiovascular system & hematology
Lower risk
Risk Assessment
03 medical and health sciences
0302 clinical medicine
SGLT2i
All-cause mortality
Risk Factors
Internal medicine
Type 2 diabetes mellitus
medicine
Humans
Diseases of the circulatory (Cardiovascular) system
Myocardial infarction
Renal Insufficiency, Chronic
Sodium-Glucose Transporter 2 Inhibitors
Original Investigation
Aged
Retrospective Studies
business.industry
Incidence
Hazard ratio
Retrospective cohort study
Middle Aged
Protective Factors
medicine.disease
Treatment Outcome
Diabetes Mellitus, Type 2
Spain
RC666-701
Female
Cardiology and Cardiovascular Medicine
business
Mace
Kidney disease
Subjects
Details
- ISSN :
- 14752840
- Database :
- OpenAIRE
- Journal :
- Cardiovascular Diabetology, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname, Dipòsit Digital de Documents de la UAB, Universitat Autònoma de Barcelona, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-11 (2021)
- Accession number :
- edsair.doi.dedup.....38325dfd280fef51822367b698968cfc